Ertugliflozin

CAS 1210344-57-2Small Molecule

Overview

Ertugliflozin is a medication used for the treatment of type 2 diabetes. It acts as an SGLT2 inhibitor, reducing blood sugar levels by preventing glucose reabsorption in the kidneys.

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Ertugliflozin expires 19 Dec 2031. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

Diabetes
Verified Supplier Partner

Do you supply Ertugliflozin? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Related APIs

Semaglutide
52 suppliers
Sitagliptin
51 suppliers
Empagliflozin
42 suppliers
Pioglitazone Hydrochloride
24 suppliers
Canagliflozin
22 suppliers
Dapagliflozin
20 suppliers
Glimepiride
17 suppliers
Repaglinide
16 suppliers

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.

Start free trialBook a demo